North East and North Cumbria
ICS Formulary
ICS Formulary
6 Endocrine system
06-07-04 Somatomedins
| Mecasermin Increlex® |
|
Formulary
|
 MHRA Drug Safety Update (Jan 2020): Mecasermin (Increlex▼): risk of benign and malignant neoplasia |
|
Links
- MHRA Drug Safety Update (Jan 2020): Mecasermin (Increlex▼): risk of benign and malignant neoplasia
- NICE HST21: Setmelanotide for treating obesity caused by LEPR or POMC deficiency
- NICE HST31: Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome
- NTAG Endocrine System Recommendations